[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100527353":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":22,"locations":30,"responsibleParty":53,"collaborators":10,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":10,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":10,"enrollmentInfo":64,"targetDuration":10,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":10,"overallStatus":45,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Participants receiving mavacamten for oHCM",null,[12],"Drug: Mavacamten",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Mavacamten","According to approved product label",[9],[20],{"name":5,"affiliation":5,"role":21},"STUDY_DIRECTOR",[23,28],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"BMS Study Connect Contact Center www.BMSStudyConnect.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":29,"role":25,"phone":10,"phoneExt":10,"email":10},"First line of the email MUST contain NCT # and Site #.",[31,43],{"facility":32,"status":33,"city":34,"state":10,"zip":35,"country":36,"countryCode":10,"cosmosGeoPoint":37,"geoPoint":42,"contacts":10},"Local Institution - 0001","TERMINATED","Seoul","06234","South Korea",{"type":38,"coordinates":39},"Point",[40,41],126.9784,37.566,{"lat":41,"lon":40},{"facility":44,"status":45,"city":34,"state":10,"zip":35,"country":36,"countryCode":10,"cosmosGeoPoint":46,"geoPoint":48,"contacts":49},"Novotech Laboratory Korea Co., Ltd.","RECRUITING",{"type":38,"coordinates":47},[40,41],{"lat":41,"lon":40},[50],{"name":51,"role":25,"phone":52,"phoneExt":10,"email":10},"South Korea Generic Country, Site 0002","0000000000",{"type":54,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100527353","a-study-to-assess-the-safety-of-mavacamten-in-korean-patients-with-symptomatic-obstructive-hypertrophic-cardiomyopathy-100527353",false,"NCT06146660","A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy","CAMZYOS® (Mavacamten) Post-Marketing Surveillance in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)","Inclusion Criteria:\n\n* Adult participants 19 years of age or older\n* Participants who receive mavacamten according to the approved product label\n* Participants who sign the informed consent form\n\nExclusion Criteria:\n\n* Participants who are prescribed mavacamten for therapeutic indications not approved in Korea\n* Participants for whom mavacamten is contraindicated as clarified in Korean prescribing information approved by the Ministry of Food and Drug Safety","ALL","19 Years",{"count":65,"type":66},600,"ESTIMATED","OBSERVATIONAL","The purpose of this observational post-marketing surveillance study is to assess the real-world safety of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult participants in Korea. Participants who will receive at least 1 dose of mavacamten will be enrolled.",[70],"Obstructive Hypertrophic Cardiomyopathy","2024-11-05",{"date":73,"type":74},"2024-11-06","ACTUAL",{"date":76,"type":74},"2024-07-24",{"date":78,"type":66},"2026-11-30",{"name":5,"class":6},2]